The endocrine subfamily of FGFs, consisting of FGF19, FGF21, and FGF23, might have beneficial effects in the treatment of diabetes mellitus (DM) and/or obesity. The gene discussed is FGF19; the disease is obesity due to melanocortin 4 receptor deficiency.